These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 21091799

  • 1. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ.
    Int J Urol; 2011 Feb; 18(2):113-20. PubMed ID: 21091799
    [Abstract] [Full Text] [Related]

  • 2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 3. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC, Steinberg GD.
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [Abstract] [Full Text] [Related]

  • 4. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F.
    Eur Urol; 2010 Mar; 57(3):410-29. PubMed ID: 19969411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [Abstract] [Full Text] [Related]

  • 7. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 8. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 9. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 10. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D, Brausi M, O'Donnell MA, Witjes JA.
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM, Morales A, Lamm DL.
    BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
    [Abstract] [Full Text] [Related]

  • 12. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR.
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [Abstract] [Full Text] [Related]

  • 13. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K.
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [Abstract] [Full Text] [Related]

  • 14. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A, Sezian N, Thwaini A.
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J.
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G.
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [Abstract] [Full Text] [Related]

  • 18. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV, Ellimoottil C, Sondej T, Flanigan RC, Quek ML.
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [Abstract] [Full Text] [Related]

  • 19. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M, Hirao Y, Akaza H, Naito S, BCG Tokyo Strain Study Group.
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [Abstract] [Full Text] [Related]

  • 20. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.